Biotech company Biogen (NASDAQ:BIIB) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 7.3% year on year to ...

NasdaqGS:BIIB 1 Year Share Price vs Fair Value Explore Biogen's Fair Values from the Community and select yours ...

A number of stocks jumped in the afternoon session after markets continued to rally amid growing speculation of an impending ...

ImmunityBio (IBRX) stock gains as its CAR-NK cell therapy shows promise in an early stage trial, with lymphoma patients ...

In addition to Scotiabank, Biogen also received a Buy from H.C. Wainwright’s Andrew Fein in a report issued today. However, on the same day, Truist Financial maintained a Hold rating on Biogen (NASDAQ ...

In a report released today, Jay Olson from Oppenheimer reiterated a Buy rating on Biogen, with a price target of $205.00. The company’s shares closed today at $128.00. Take advantage of TipRanks ...

Biogen CEO Chris Viehbacher says Novo Nordisk's Alzheimer's trial success could lead to combination therapies, boosting ...

With a market cap of $3.1 billion, Scholar Rock Holding Corporation appears fairly valued for now. Click here to read an ...

Anavex faces dilution risk from its $150M ATM facility, high cash burn, and lack of revenue. Click here to see why AVXL stock ...

Major indices were in the green early on Wednesday, with the S&P 500 and Nasdaq Composite building on yesterday's ...

Major indices delivered a mixed performance on Thursday after Donald Trump's newly announced chip tariffs included broad ...